Spots Global Cancer Trial Database for hepatocellular
Every month we try and update this database with for hepatocellular cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma | NCT00051545 | Liver Neoplasms | Seocalcitol | 18 Years - 75 Years | LEO Pharma | |
| Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC | NCT01963429 | Recurrent Small... Residual Small ... | radiofrequency ... Proton beam the... | 18 Years - | National Cancer Center, Korea | |
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| On the Cyberknife Dose Fraction of Liver Cancer Treatment | NCT03295500 | CyberKnife Radi... | Dose fraction f... | 30 Years - 80 Years | Beijing 302 Hospital | |
| Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | NCT03908840 | Hepatocellular ... | TBI 302 | 18 Years - | Therapure Biopharma Inc | |
| Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) | NCT04170556 | Hepatocellular ... | Regorafenib Nivolumab | 18 Years - | Fundacion Clinic per a la Recerca Biomédica | |
| Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | NCT00073736 | Hepatocellular ... | MB07133 300mg/m... MB07133 600 mg/... MB07133 1200 mg... MB07133 1800 mg... MB07133 2400 mg... | 18 Years - | Ligand Pharmaceuticals | |
| Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison | NCT04823715 | Non-metastatic ... | TACE + hypofrac... Surgical resect... | 18 Years - | Hospices Civils de Lyon | |
| Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma | NCT00051532 | Liver Neoplasms | Seocalcitol | 18 Years - 75 Years | LEO Pharma | |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | NCT01755767 | Hepatocellular ... | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Study of Minnelide™ in Patients With Advanced GI Tumors | NCT01927965 | Advanced Gastro... | Minnelide™ 001 | 18 Years - | Minneamrita Therapeutics LLC | |
| Adjuvant TACE to Reduce the HCC Recurrence After Resection | NCT02788526 | Carcinoma, Hepa... | Adjuvant TACE Follow-up | 18 Years - 75 Years | Sun Yat-sen University | |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | NCT02323906 | Carcinoma, Hepa... | CC-122 Sorafenib | 18 Years - | Celgene | |
| Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | NCT02323906 | Carcinoma, Hepa... | CC-122 Sorafenib | 18 Years - | Celgene | |
| Investigation of Immune Modulation by Modern Acupuncture in Gastroenterologic Cancers | NCT04692454 | Hepatocellular ... Gastrointestina... Immunosuppressi... | Modern acupunct... | 20 Years - 75 Years | Taipei Medical University WanFang Hospital | |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | NCT01755767 | Hepatocellular ... | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma | NCT02269995 | Hepatocellular ... | E7040 | - | Eisai Inc. | |
| Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation | NCT04555265 | Hepatocellular ... | Radiofrequency ... | 18 Years - | Chinese University of Hong Kong | |
| Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | NCT00988741 | Unresectable He... | ARQ 197 Placebo | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter | NCT00250822 | Liver Cancer | Gemcitabine and... | 18 Years - | New Mexico Cancer Care Alliance | |
| Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | NCT03908840 | Hepatocellular ... | TBI 302 | 18 Years - | Therapure Biopharma Inc | |
| Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC | NCT01963429 | Recurrent Small... Residual Small ... | radiofrequency ... Proton beam the... | 18 Years - | National Cancer Center, Korea | |
| Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | NCT01755767 | Hepatocellular ... | Tivantinib Placebo | 18 Years - | Daiichi Sankyo | |
| Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter | NCT00250822 | Liver Cancer | Gemcitabine and... | 18 Years - | New Mexico Cancer Care Alliance | |
| ABT-888 and Temozolomide for Liver Cancer | NCT01205828 | Hepatocellular ... | Temozolomide ABT-888 | 18 Years - | Georgetown University | |
| Investigation of Immune Modulation by Modern Acupuncture in Gastroenterologic Cancers | NCT04692454 | Hepatocellular ... Gastrointestina... Immunosuppressi... | Modern acupunct... | 20 Years - 75 Years | Taipei Medical University WanFang Hospital | |
| Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | NCT00073736 | Hepatocellular ... | MB07133 300mg/m... MB07133 600 mg/... MB07133 1200 mg... MB07133 1800 mg... MB07133 2400 mg... | 18 Years - | Ligand Pharmaceuticals | |
| Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma | NCT02269995 | Hepatocellular ... | E7040 | - | Eisai Inc. | |
| Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) | NCT00946153 | Hepatocellular ... | Lenvatinib | 20 Years - 80 Years | Eisai Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
